

1F-151-T025

Monoclonal Antibody to CD49b / Integrin alpha 2 Fluorescein (FITC) conjugated (25 tests)

Clone: AK7

Isotype: Mouse IgG1

Specificity: The mouse monoclonal antibody AK7 recognizes CD49b, a 160-165 kDa alpha

subunit of VLA-2 integrin complex expressed on platelets, megakaryocytes, activated T and B cells, monocytes, epithelial cells, endothelial cells and

fibroblasts.

HLDA Workshop code V S190

Regulatory Status: RUO

Immunogen: Human platelets

Species Reactivity: Human, Non-Human Primates

Preparation: The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under

optimum conditions. The reagent is free of unconjugated FITC and adjusted for

direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using 4

μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension.

The content of a vial (0.1 ml) is sufficient for 25 tests.

Expiration: See vial label

Lot Number: See vial label

Background: CD49b / Integrin alpha 2 (ITGA2; alpha 2 subunit of VLA-2) heterodimerizes with

CD29 to form the VLA-2 integrin alpha2/beta1 complex, which serves as a receptor for type I collagen, laminin, and E-cadherin. It also acts as a receptor for echovirus. Expressed on platelets, activated lymphocytes, monocytes, fibroblasts, epitelial and endothelial cells, CD49b mediates adhesion of these cells to the extracellular matrix. This interaction supports e.g. T cell proliferation and cytokine production, or wound healing. Defect in CD49b is associated with bleeding disorder platelet-type 9. Antibodies against CD49b are found in several immune disorders, including

neonatal alloimmune thrombocytopenia.



PRODUCT DATA SHEET

References:

*Gamble JR, Matthias LJ, Meyer G, Kaur P, Russ G, Faull R, Berndt MC, Vadas MA: Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol. 1993 May;121(4):931-43.

*Londrigan SL, Hewish MJ, Thomson MJ, Sanders GM, Mustafa H, Coulson BS: Growth of rotaviruses in continuous human and monkey cell lines that vary in their expression of integrins. J Gen Virol. 2000 Sep;81(Pt 9):2203-13.

*Werr J, Johansson J, Eriksson EE, Hedqvist P, Ruoslahti E, Lindbom L: Integrin alpha(2)beta(1) (VLA-2) is a principal receptor used by neutrophils for locomotion in extravascular tissue. Blood. 2000 Mar 1;95(5):1804-9.

*Ammon C, Meyer SP, Schwarzfischer L, Krause SW, Andreesen R, Kreutz M: Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells. Immunology. 2000 Jul;100(3):364-9.

*Ciarlet M, Crawford SE, Cheng E, Blutt SE, Rice DA, Bergelson JM, Estes MK: VLA-2 (alpha2beta1) integrin promotes rotavirus entry into cells but is not necessary for rotavirus attachment. J Virol. 2002 Feb;76(3):1109-23.

*Kögler G, Sensken S, Airey JA, Trapp T, Müschen M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bender J, Degistirici O, Gao J, Caplan AI, Colletti EJ, Almeida-Porada G, Müller HW, Zanjani E, Wernet P: A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med. 2004 Jul 19;200(2):123-35.

*Müller K, Schinn M, Reichrath J, Meineke V: 1alpha,25-Dihydroxyvitamin D3 modulates the response of human keratinocytes to ionizing radiation exposure. Anticancer Res. 2006 Jul-Aug;26(4A):2735-41.

*Engl T, Makarević J, Relja B, Natsheh I, Müller I, Beecken WD, Jonas D, Blaheta RA: Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer. 2005 Jan 11;5:4.

*Sutavani RV, Bradley RG, Ramage JM, Jackson AM, Durrant LG, Spendlove I: CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype. J Immunol. 2013 Dec 15;191(12):5895-903.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.